Premium
Borderline CD30+ cutaneous lymphoproliferative disorder: report of a case with expression of cytotoxic markers and response to clarithromycin
Author(s) -
Ponte Pedro,
Serrão Vasco,
Viana Isabel,
Vale Esmeralda,
João Alexandre,
Cerroni Lorenzo
Publication year - 2011
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/j.1600-0560.2009.01476.x
Subject(s) - cytotoxic t cell , clarithromycin , pathology , cd30 , lymphoproliferative disorders , medicine , immunology , lymphoma , biology , helicobacter pylori , biochemistry , in vitro
CD30+ cutaneous lymphoproliferative disorders (CLPDs) are usually characterized by a benign clinical course. The prognostic value of cytotoxic markers in these lymphomas has not been evaluated in large series. We describe a case of borderline CD30+ CLPD with cytotoxic phenotype, presenting in a 22‐year‐old male patient as an ulcer on the forearm. He reported having had similar ulcers on the buttock and thigh that spontaneously regressed over the course of 1 year. The lesion resolved with a single course of clarithromycin; a subsequent lesion, too, responded to clarithromycin, and no recurrences or systemic involvement have been documented in the 9‐month follow‐up. A conservative approach in the management of CD30+ CLPD is recommended. We believe that the anti‐inflammatory and apoptotic effects of clarithromycin on T cells may have hastened the remission process. Ponte P, Serrão V, Viana I, Vale E, João A, Cerroni L. Borderline CD30+ cutaneous lymphoproliferative disorder: report of a case with expression of cytotoxic markers and response to clarithromycin.